Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC increased its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,625 shares of the medical research company’s stock after purchasing an additional 269 shares during the period. Sanctuary Advisors LLC’s holdings in Exact Sciences were worth $763,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Huntington National Bank grew its holdings in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in shares of Exact Sciences in the third quarter worth approximately $34,000. Capital Performance Advisors LLP purchased a new stake in Exact Sciences in the third quarter valued at approximately $35,000. Asset Planning Inc acquired a new position in Exact Sciences during the fourth quarter worth approximately $40,000. Finally, Modus Advisors LLC purchased a new position in Exact Sciences during the fourth quarter worth approximately $43,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $47.82 on Friday. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The stock has a market cap of $8.88 billion, a P/E ratio of -8.59 and a beta of 1.24. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The firm has a 50-day moving average of $54.17 and a two-hundred day moving average of $59.79.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. On average, research analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on EXAS shares. BTIG Research boosted their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. The Goldman Sachs Group lowered their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Craig Hallum cut their price objective on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Evercore ISI decreased their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Citigroup cut their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $71.94.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.